Codexis is a biotechnology company that engineers enzymes for pharmaceutical, fine chemicals, flavors & fragrances, agrochemicals and more. Codexis engineers custom enzymes and microorganisms, which are sometimes referred to as biocatalysts. The Company's Codexis' proprietary technology called CodeEvolver is directed evolution technology based on the concept that natural genetic mutation and selection can be accelerated in the research laboratory to obtain specific improvements in the function of single proteins and multiprotein pathways. CodeEvolver combines DNA shuffling and bioinformatics with systems biology to create new biocatalysts.


Employee Rating

2.9More
TypePublic
HQRedwood City, US
Founded2002
Size (employees)116 (est)+10%
Websitecodexis.com
Codexis was founded in 2002 and is headquartered in Redwood City, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Codexis

John Nicols

John Nicols

President & CEO
James Lalonde

James Lalonde

Senior Vice President, Research & Development
Show more

Codexis Office Locations

Codexis has an office in Redwood City
Redwood City, US (HQ)
200 Penobscot Dr
Show all (1)
Report incorrect company information

Codexis Financials and Metrics

Codexis Revenue

Codexis's revenue was reported to be $50.02 m in FY, 2017
USD

Revenue (Q3, 2018)

16.9m

Net income (Q3, 2018)

(2.0m)

EBIT (Q3, 2018)

(2.1m)

Market capitalization (14-Dec-2018)

1.1b

Closing stock price (14-Dec-2018)

19.5

Cash (30-Sep-2018)

54.2m
Codexis's current market capitalization is $1.1 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

31.9m35.3m41.8m48.8m50.0m

Revenue growth, %

11%18%17%

Cost of goods sold

9.8m14.3m

Gross profit

39.1m35.7m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

3.9m7.1m6.6m7.5m6.8m6.0m17.4m8.0m16.0m14.9m8.0m10.3m10.0m14.0m13.5m16.9m

Cost of goods sold

3.0m3.8m4.0m

Gross profit

5.0m6.6m6.0m

Gross profit Margin, %

62%63%60%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

22.1m26.5m23.3m19.2m31.2m

Accounts Receivable

Inventories

1.5m1.4m992.0k825.0k1.0m

Current Assets

35.8m33.0m32.8m27.2m45.0m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

26.9m23.2m20.1m21.5m22.2m16.6m17.0m22.2m22.4m14.9m13.9m28.8m23.8m24.3m53.6m54.2m

Inventories

2.1m2.0m2.0m1.9m992.0k968.0k678.0k1.0m1.2m1.1m1.1m806.0k849.0k1.2m1.0m830.0k

Current Assets

36.6m34.2m26.9m28.2m27.6m21.4m32.3m28.8m27.9m30.1m21.7m40.4m35.0m36.0m66.3m68.5m

PP&E

13.8m7.4m4.9m4.4m3.5m3.2m2.8m2.8m2.4m2.3m2.8m3.0m2.8m2.6m3.9m4.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(41.3m)(19.1m)(7.6m)(8.6m)(23.0m)

Depreciation and Amortization

1.0m

Inventories

(185.0k)92.0k403.0k167.0k(210.0k)

Accounts Payable

308.0k713.0k(1.3m)942.0k(801.0k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(31.5m)(6.4m)(14.9m)(19.4m)(5.6m)(10.9m)(5.5m)(7.0m)(4.7m)(3.3m)(7.5m)(13.7m)(24.0m)(4.7m)(8.4m)(10.4m)

Depreciation and Amortization

795.0k238.0k503.0k812.0k

Inventories

(614.0k)(557.0k)(476.0k)(456.0k)992.0k427.0k717.0k1.0m(163.0k)(84.0k)(299.0k)19.0k(24.0k)(177.0k)206.0k

Accounts Payable

(2.2m)(472.0k)(631.0k)(1.4m)2.0m(3.0m)(3.5m)(395.0k)(492.0k)(1.0m)(882.0k)(446.0k)150.0k(975.0k)(530.0k)(1.7m)
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information

Codexis Online and Social Media Presence

Embed Graph
Report incorrect company information

Codexis News and Updates

Codexis Announces Results of Phase 1a Clinical Trial with CDX-6114

CDX-6114 meets safety and tolerability endpoints

Codexis to Hold Second Quarter 2018 Conference Call on August 8

REDWOOD CITY, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2018 financial results after market close on Wednesday, August 8, 2018. Codexis management will hold an investment community con…

Phenylketonuria (PKU) Market Key Players – American Gene Technologies International Inc, BioMarin Pharmaceutical Inc, Censa Pharmaceuticals Inc, Codexis Inc Analysis and Forecast to 2022

WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Phenylketonuria (PKU) - Pipeline Review, H1 2018” Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information

Codexis Company Life and Culture

Report incorrect company information

Codexis Frequently Asked Questions

  • When was Codexis founded?

    Codexis was founded in 2002.

  • Who are Codexis key executives?

    Codexis's key executives are John Nicols and James Lalonde.

  • How many employees does Codexis have?

    Codexis has 116 employees.

  • What is Codexis revenue?

    Latest Codexis annual revenue is $50 m.

  • What is Codexis revenue per employee?

    Latest Codexis revenue per employee is $431.2 k.

  • Who are Codexis competitors?

    Competitors of Codexis include Creative Biolabs, IQVIA and Hoth Therapeutics.

  • Where is Codexis headquarters?

    Codexis headquarters is located at 200 Penobscot Dr, Redwood City.

  • Where are Codexis offices?

    Codexis has an office in Redwood City.

  • How many offices does Codexis have?

    Codexis has 1 office.